DEFA14A: InMed Pharmaceuticals Urges Shareholder Approval for Standby Equity Purchase Agreement to Bolster Financial Flexibility

InMed Pharmaceuticals Inc. is reminding shareholders to vote on a proposal to approve the potential issuance of 20% or more of its common shares under a Standby Equity Purchase Agreement (SEPA) to secure future funding.

Summary

• InMed Pharmaceuticals Inc. is holding a Special Meeting of Shareholders virtually on Friday, June 13, 2025, at 10:00 a.m. Pacific Time.
• The primary purpose of the meeting is to seek shareholder approval, in accordance with Nasdaq Listing Rules 5635(d) and 5636(b), for the potential issuance of 20% or more of the company's issued and outstanding common shares.
• This potential issuance is pursuant to a Standby Equity Purchase Agreement (SEPA) entered into with YA II PN, Ltd., an investment fund managed by Yorkville Advisors Global LP, on December 13, 2024.
• The Board of Directors believes the SEPA is a low-cost option to raise capital expeditiously and fund company operations.
• Shareholder approval is expected to enhance InMed's financial flexibility and avoid potentially more costly and dilutive alternative financing options.
• Proxy materials containing important information were previously sent to shareholders on or about May 16, 2025.
• Shareholders are encouraged to vote by Internet or mail, with the deadline for submission being June 11, 2025, at 10:00 a.m. Pacific Time.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the company is proactively seeking shareholder approval for a financing mechanism (SEPA) that management believes is a low-cost and expeditious way to secure capital and enhance financial flexibility. While it involves potential dilution, it's framed as a necessary and beneficial step for a growth-stage company, avoiding potentially worse alternatives.

Positives

• The Standby Equity Purchase Agreement (SEPA) is presented as a low-cost option for InMed Pharmaceuticals to raise capital.
• The SEPA is expected to enable the company to raise capital expeditiously, supporting ongoing operations.
• Gaining shareholder approval for the SEPA is anticipated to enhance InMed's financial flexibility.
• Approval of the SEPA could help the company avoid incurring additional costs and obligations that might arise from alternative financing options.

Negatives

• If the proposal to approve the SEPA is not approved by shareholders, InMed Pharmaceuticals may be compelled to explore alternative financing options.
• Alternative financing options are likely to be more costly for the company.
• Such alternatives could impede the company from raising capital readily in the near term.
• Alternative financing options are also likely to be more dilutive to the company's shareholders than the SEPA.

Risks

• Failure to obtain shareholder approval for the Standby Equity Purchase Agreement (SEPA) could force the company to pursue alternative financing options that are likely to be more costly.
• Lack of SEPA approval may impede the company's ability to raise capital readily in the near term.
• Alternative financing options, if pursued due to non-approval of the SEPA, are expected to be more dilutive to existing shareholders.

Future Outlook

The company anticipates that gaining shareholder approval for the Standby Equity Purchase Agreement (SEPA) will enhance its financial flexibility and enable it to raise capital expeditiously to fund operations. Conversely, non-approval could lead to more costly and dilutive alternative financing options, potentially impeding near-term capital raising.

Management Comments

• "InMed's Board of Directors believes the SEPA represents a low-cost option that will enable the Company to raise capital expeditiously to fund the Company's operations."
• "Gaining shareholder approval at the Meeting is expected to enhance InMed's financial flexibility without introducing additional costs and obligations that could be incurred if alternative financing options were pursued."
• "If the proposal presented at the Meeting is not ultimately approved by the Company's shareholders, the Company may be compelled to explore alternative financing options, any of which are likely to be more costly, impede the Company from raising capital more readily in the near term, and more dilutive to the Company's shareholders."

Industry Context

Obtaining shareholder approval for significant share issuances, such as the one proposed by InMed Pharmaceuticals, is described as common practice for growth-stage companies, particularly within the pharmaceutical industry, as they often rely on equity financing to fund research, development, and operational growth.

Comparison to Industry Standards

• The company states that obtaining shareholder approval for such matters (issuance of 20% or more of common shares) is common practice for growth-stage companies, including within the pharmaceutical industry.
• This aligns with typical financing strategies for early to mid-stage pharmaceutical companies that require substantial capital for drug development and clinical trials, often through equity raises.

Corporate Governance

Stakeholder Impact

• **Shareholders**: Potential dilution of existing shareholdings if the 20% or more share issuance is approved and executed. However, approval is intended to enhance the company's financial flexibility and avoid more dilutive alternatives.
• **Company Operations**: The capital raised through the SEPA is intended to fund the company's operations, supporting its growth initiatives and strategic objectives.

Next Steps

• Shareholders are required to vote on the proposal to approve the potential issuance of shares under the SEPA.
• The Special Meeting of Shareholders will be held virtually on June 13, 2025, to consider the proposal.
• If approved, the company intends to utilize the SEPA to raise capital to fund its operations.

Key Dates

Keywords

InMed Pharmaceuticals, SEC filing, DEFA14A, proxy statement, shareholder meeting, capital raise, Standby Equity Purchase Agreement, SEPA, equity financing, dilution, Nasdaq Listing Rules, pharmaceuticals, biotechnology, corporate governance, financial flexibility